We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Worldwide POC Diagnostics Market to Grow

By Labmedica staff writers
Posted on 07 Aug 2006
The worldwide point-of-care (POC) diagnostics market is about to undergo exceptional growth, according to a new report compiled by Cambridge Consultants (Cambridge Science Park, UK).

The report was released following a workshop held in May 2006 by Cambridge Consultants. More...
The participants, who came from across the diagnostics industry, discussed the future of point-of-care testing (POCT) and the role of technology. Attending the 24-hour workshop were delegates from a variety of backgrounds, including clinicians and representatives of diagnostic companies.

Increased availability of accurate, rapid tests, patient demand for instant results, integration with drug delivery technology, and a general shift from lab-based tests to testing in the home, in doctor's surgeries, and over the pharmacy counter were the reasons given for the expected increase in the POCT domestic market.

The delegates questioned whether the technology was adequate. They agreed that the current wet chemistry used in diagnostic testing is adequate and that the barriers to faster adoption lie in post-test data management and quality control. However, the delegation also agreed that new and emerging technologies, such as micro- and nano-technology and novel labels, could revolutionize POCT and diagnostic testing in the future. The group felt that in the meantime those in the industry need to work together to enable doctors and patients to collate the results of the tests. In addition, standardization is necessary to speed adoption of POCT technology, as well as to provide the patient with a common user interface.

The market for POCT differs from region to region. In the United States, defensive medicine dominates, and concerns over liability means that a final confirmatory central test is required. In Europe, adoption depends on clinical benefits and centralized purchasing, and the rate of acceptance is different within each country. In countries like Sweden and Germany, which have decentralized health services, POCT uptake is moving fast with high awareness among doctors and patients. The United Kingdom's difficulty in employing information technology (IT) on time and within budget suggests that countries with similar centralized health services might struggle with POCT adoption.

"Diagnostics could learn a lot from the phone industry,” said Dr. Burnell, diagnostics campaign manager at Cambridge Consultants. "As a group they came together to focus on standardizing aspects of their technology as they realized that this would benefit the customer, as well as the companies who were then free to innovate and add value. The diagnostics industry needs to follow suit and work out a way of providing data from point-of-care devices in a simple and common format.”



Related Links:
Cambridge Consultants

New
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Serological Pipet Controller
PIPETBOY GENIUS
New
Specimen Radiography System
TrueView 200 Pro
New
Automatic Hematology Analyzer
LABAS F9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: EvoLiver is the first test to receive FDA Breakthrough Device Designation in five years in the liver cancer surveillance space (Photo courtesy of Mursla Bio)

Patient-Friendly Blood Test to Transform Liver Cancer Surveillance

Hepatocellular carcinoma (HCC), the most common form of primary liver cancer, is the fastest-growing cause of cancer-related deaths. Although clinical guidelines recommend routine surveillance for high-risk... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: CellLENS enables the potential precision therapy strategies against specific immune cell populations in the tissue environment (Photo courtesy of MIT)

New AI System Uncovers Hidden Cell Subtypes to Advance Cancer Immunotherapy

To produce effective targeted therapies for cancer, scientists need to isolate the genetic and phenotypic characteristics of cancer cells, both within and across different tumors. These differences significantly... Read more

Technology

view channel
Image: The Check4 gene-detection platform (Photo courtesy of IdentifySensors)

Electronic Biosensors Used to Detect Pathogens Can Rapidly Detect Cancer Cells

A major challenge in healthcare is the early and affordable detection of serious diseases such as cancer. Early diagnosis remains difficult due to the complexity of identifying specific genetic markers... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.